Fresenius - the health care group
The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.
Fresenius SE & Co KGaA will be included in the EURO STOXX 50 blue-chip index on September 21, 2015. The index update was announced by the Deutsche Börse subsidiary STOXX after the close of trading on Monday night. >>>
Fresenius Medical Care has released a new single-use adsorber for the treatment of IgE (ImmunoglobulinE)-mediated diseases in the European market. >>>
Fresenius expects a significant 2015 dividend increase, resulting from the forecasted 2015 net income growth applied to the company’s dividend policy. After raising guidance twice this year, Fresenius is forecasting 2015 net income growth of 18% to 21% in constant currency.>>>
Ulf Mark Schneider, CEO of Fresenius, said: “Our strong growth trend continues in all four business segments. In times of economic volatility, our broad geographic presence and well-diversified business provide reliable growth and continue to contribute to Fresenius’ overall success. We are highly confident of our Company’s growth prospects and raise our Group earnings guidance.” >>>
Rice Powell, chief executive officer of Fresenius Medical Care stated: “Our second quarter 2015 results showed a positive underlying performance. We are pleased with our revenue and earnings growth considering the negative currency impact on our International operations in the second quarter. [...]" >>>